Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer

Creatv Bio’s LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Liquid Biopsy Predicts Esophageal Cancer Patient Response to Treatment

Pan-Cancer Blood Test Addresses Major Unmet Needs

Creatv MicroTech Aims to Detect Patient Immune Cells for Cancer Drug Response Prediction

LifeTracDx Blood Test Shows Positive Results in Detection of Early Stage Cancer in Solid Tumors

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

Creatv Announces Positive Results for the LifeTracDx Blood Test in the Detection of Early Stage Cancer in Multiple Solid Tumors

Creatv’s LifeTracDx Blood Test for Early Detection of Aggressive Prostate Cancer

AACR Exhibit and Poster Presentations

Creatv MicroTech Receives Japanese Patent for Cancer Screening

DoD Funding for Lung Cancer Screening (September 2018)

NIH/NCI SBIR Grant (August 2017)

Early detection of breast cancer, highlighted in Cancer Epidemiology, Biomarkers & Prevention, http://cebp.aacrjournals.org/content/25/7/1007

Ian C. Clift, Driving Cancer Immunotherapy, GEN Translational Medicine, April 1, 2016 (on pages 1, 32-35), http://gen.epubxp.com/i/654153-apr1-2016/34

DARPA contract (December 8, 2014)

Andrew Pollack, Sidestepping the Biopsy with New Tools to Spot Cancer, NY Times, April 7, 2014. http://www.nytimes.com/2014/04/08/business/cancer-analysis-tools-circumvent-biopsies.html?_r=1

Cancer associated giant macrophages-like cells (March 11, 2014)

BioScience Company of the Year Award (2013)

SNN interview (August 29, 2012)